Key result
Higher serum ANGPTL4 levels were independently associated with cognitive impairment in patients with cerebral small vessel disease (OR 2.062; 95% CI 1.591-2.674; p < 0.001).
Why the study?
To investigate the correlation between serum ANGPTL4 levels, white matter hyperintensity, and cognitive impairment in patients with cerebral small vessel disease.
Is there a correlation between serum ANGPTL4 levels, white matter hyperintensity, and cognitive impairment in patients with cerebral small vessel disease?
Cross-Sectional (n=171)
No
Is there a correlation between serum ANGPTL4 levels, white matter hyperintensity, and cognitive impairment in patients with cerebral small vessel disease?
Odds Ratio: 2.062 (95% CI 1.591–2.674)
p-value: p=<.001
Serum ANGPTL4 levels are independently associated with cognitive impairment and white matter hyperintensity severity in patients with cerebral small vessel disease.
ANGPTL4 associated with WMH and CI in CSVD; hypothesis-generating for biomarker role, prospective studies required before adoption.
OBJECTIVES: To investigate the correlation between serum angiopoietin-like protein 4 (ANGPTL4) levels, white matter hyperintensity (WMH), and cognitive impairment (CI) in patients with cerebral small vessel disease (CSVD). METHODS: This cross-sectional study enrolled 171 patients with CSVD who attended the First Affiliated Hospital of Xinxiang Medical University from December 2021 to July 2022. All subjects underwent a 3.0T head magnetic resonance imaging, neuropsychology assessment, and blood sampling. Serum ANGPTL4 levels were detected by enzyme-linked immunosorbent assay and the severity of WMH was assessed by the Fazekas scale. According to the Montreal Cognitive Assessment (MoCA) scale, subjects were divided into normal cognition group (NC, n = 80) and CI group (n = 91). According to the total Fazekas scores, subjects were divided into a mild WMH group (n = 84), a moderate WMH group (n = 70), and a severe WMH group (n = 17). RESULTS: Serum ANGPTL4 levels were significantly higher in the CI group than in the NC group (p < .05) and were negatively correlated with mini-mental state examination scores and MoCA scores (r = -0.26, -0.341, p < .05). Serum ANGPTL4 levels increased significantly in the mild to moderate WMH group but tended to decrease in the severe WMH group. Binary logistic regression analysis showed that ANGPTL4 was an independent influencing factor for CSVD-CI (OR = 2.062, 95% CI (1.591-2.674), p < .001). The area under curve of ANGPTL4 for CSVD-CI was 0.847 (0.791-0.903). CONCLUSION: ANGPTL4 may be involved in the process of white matter damage and CI in CSVD patients and shows a diagnostic value for CSVD-CI.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2024) conducted a cross-sectional in Cerebral small vessel disease (CSVD) (n=171). Serum ANGPTL4 levels vs. Normal cognition was evaluated on Cognitive impairment (CSVD-CI) (OR 2.062, 95% CI 1.591-2.674, p=<.001). Higher serum ANGPTL4 levels were independently associated with cognitive impairment in patients with cerebral small vessel disease (OR 2.062; 95% CI 1.591-2.674; p < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: